Use and Effectiveness of Carboximaltose Iron in Preoperative Anemia Treatment: A Multicenter and Retrospective Study

Abstract

Angel Manuel Yuste Gutierrez,1 Marta Alonso-Moreno,2 Jose Luis Perez Blanco,2 David Berlana,3 Maria Angeles Peña Fernandez,4 Maria Teresa Perez Maroto,1 Miguel Torralba5 1Pharmacy Department, Guadalajara University Hospital, Guadalajara, Spain; 2Pharmacy Department, Virgen del Rocío University Hospital, Sevilla, Spain; 3Pharmacy Department, Vall d’Hebron University Hospital, Barcelona, Spain; 4Biomedical Science Department, Universidad de Alcalá de Henares, Madrid, Spain; 5Internal Medicine Department, Guadalajara University Hospital, Guadalajara, SpainCorrespondence: Angel Manuel Yuste Gutierrez, Email [email protected]: Anemia, primarily due to iron deficiency, is a key risk factor in both elective and emergency surgeries. Immediate preoperative treatment with ferric carboxymaltose (FCM) in anemic patients can reduce the need for transfusions and the length of hospital stay, thereby optimizing surgical outcomes. The objective of this study was to assess the effectiveness and describe the use of administering intravenous FCM prior to elective scheduled surgery for patients diagnosed with anemia.Methods: Multicenter, retrospective cohort study that encompassed patients aged 18 years and older who underwent surgery between January 2017 and December 2018. Demographic variables, dose scheme, baseline and perioperative haemoglobin (Hb), transfusion requirements, and admission days were collected. The primary endpoints were the response rate and effectiveness of FCM, defined as the proportion of patients with Hb preoperative levels of ≥ 13 g/dL. A patient response was deemed to occur when Hb level increased by 1 g/dL or more. The secondary endpoints were the appropriateness of FCM dose, transfusion requirement rate, and length of hospital stay.Results: 446 patients (55.2% women, median age 69 IQR:52– 78 years) were included. The median total dose of FCM administered was 1000 mg over a span of 5 day (IQR: 0– 16) days before surgery. 62.8% of patients received lower doses, 24.9% had an INCREASE of Hb ≥ 1 g/dL, 11.6% had Hb ≥ 13 g/dL and 21.3% required blood transfusions, with a mean of 0.73 units transfused. The length of the hospital stay was 12 days (IQR:6– 23).Conclusion: Low percentage of patients achieved a hemoglobin level of 13 g/dL or experienced an increase in hemoglobin of 1 g/dL or more following the administration of FCM, indicating the low effectiveness of FCM in treating perioperative anaemia in our surgical patients. There is underdosing of FCM and insufficient time between FCM administration and surgery in most patients. Both transfused and non-transfused patients show similar Hb increases, while those receiving a standard 1000 mg dose of FCM experience shorter hospital stays compared to those receiving 500 mg, and patients with more transfusions have longer hospital stays.Keywords: iron intravenous administration, ferric carboxymaltose, iron deficiency anemia

Keywords

• iron intravenous administration
• ferric carboxymaltose
• iron deficiency anemia